Clinical Pharmacology of Topical Drug Absorption Across Altered Skin Microenvironments

Abstract

The clinical pharmacology of topical drug absorption is a critical aspect of dermatologic therapeutics, influenced profoundly by the integrity and characteristics of the skin microenvironment. Altered skin due to disease, trauma, or external insults can significantly modify the pharmacokinetics and pharmacodynamics of topically applied agents. This review synthesizes current evidence on the mechanisms of cutaneous absorption, the impact of pathological skin changes, and the clinical implications for optimizing topical therapy. Consideration of disease burden, pathogenesis, risk factors, clinical presentation, diagnostic strategies, and management approaches is essential for safe and effective use of topical pharmacotherapy. The review concludes with recent advances, emerging therapies, and guideline-driven recommendations for clinicians managing patients with compromised skin barriers.

Introduction

Topical drug administration is a cornerstone of dermatologic and wound care practice, offering the advantage of localized therapy with reduced systemic exposure. However, the skin's function as a barrier is highly dynamic and can be disrupted by a variety of pathological states, including eczema, psoriasis, burns, and chronic wounds. These alterations can facilitate or impede drug absorption, thereby impacting clinical efficacy and safety. Understanding the interplay between drug properties, formulation, and the altered skin microenvironment is crucial for healthcare professionals aiming to optimize therapeutic outcomes.

Epidemiology / Disease Burden

Globally, skin disorders constitute a significant proportion of non-fatal disease burden. According to the Global Burden of Disease Study 2019, conditions such as atopic dermatitis, psoriasis, chronic ulcers, and burns collectively affect hundreds of millions worldwide. The prevalence of chronic wounds, particularly in aging populations and those with diabetes, is rising, leading to increased use of topical therapies. The frequency of topical drug exposure in patients with skin barrier compromise underscores the importance of understanding pharmacologic implications in these populations.

Pathophysiology

The stratum corneum is the principal barrier to percutaneous absorption, composed of corneocytes embedded in lipid lamellae. Pathological states disrupt this structure, either by direct loss of barrier (e.g., ulcerations, burns) or by inflammatory processes that alter lipid composition and hydration (e.g., eczema, psoriasis). These changes can increase transepidermal water loss and permeability, facilitating enhanced absorption of topical agents. Conversely, hyperkeratotic conditions may impede absorption by increasing diffusional distance and altering drug partitioning.

Risk Factors

Key risk factors for altered topical drug absorption include age (infants and elderly), pre-existing dermatoses, systemic diseases (such as diabetes mellitus), immunosuppression, and environmental exposures (UV radiation, chemical irritants). The use of occlusive dressings, high-potency formulations, or application to large surface areas further amplifies the risk of systemic absorption and adverse effects, especially in compromised skin.

Clinical Features

Clinicians must recognize signs of altered drug absorption, which may manifest as exaggerated local or systemic effects. Cutaneous features include increased erythema, atrophy, striae, or contact dermatitis, while systemic toxicity may present as hypothalamic-pituitary-adrenal axis suppression in the case of topical corticosteroids. Patients with chronic wounds or extensive burns are at highest risk for unintended systemic exposure and sequelae.

Diagnosis

Assessment involves careful clinical evaluation of skin integrity, disease extent, and the presence of risk factors for altered absorption. Quantitative methods such as transepidermal water loss measurement, bioimpedance spectroscopy, and non-invasive imaging (reflectance confocal microscopy) may provide adjunctive information. Pharmacokinetic studies, while not routinely performed, offer valuable insight in research or complex clinical scenarios.

Treatment & Management

Optimal management of topical drug therapy in altered skin environments requires individualized assessment. Selection of drug, vehicle, concentration, and dosing frequency should be tailored to the degree of barrier disruption. Non-occlusive formulations and the use of lower-potency agents are preferred in high-risk patients. Monitoring for local and systemic adverse effects is essential, particularly when treating infants, elderly, or those with large or ulcerated lesions. Adjunctive measures such as barrier repair emollients may help restore skin integrity and modulate drug absorption dynamics.

Recent Advances / Emerging Therapies

Recent years have witnessed the development of novel drug delivery systems including liposomes, nanoparticles, and microneedle arrays designed to enhance targeted delivery while minimizing systemic exposure. Advances in understanding the molecular basis of skin barrier defects have led to the development of barrier-enhancing adjuvants and personalized formulations. Clinical trials increasingly emphasize pharmacogenomics and biomarker-driven approaches to optimize topical therapy in patients with altered skin microenvironments.

Guideline Recommendations

Contemporary guidelines from dermatologic societies recommend a cautious approach to topical drug use in patients with compromised skin. Key principles include starting with the lowest effective dose, avoiding high-potency or systemic-absorbing agents in vulnerable populations, and regular monitoring for adverse effects. Multidisciplinary collaboration with pharmacists, wound care specialists, and primary care providers is advocated to ensure safe and effective therapy.

Conclusion

The clinical pharmacology of topical drug absorption is profoundly modulated by alterations in the skin microenvironment. Healthcare professionals must integrate knowledge of pathophysiology, risk factors, and patient-specific variables to optimize topical therapy. Recent advances in drug delivery and barrier restoration hold promise for safer and more effective management. Ongoing research and adherence to evidence-based guidelines will further enhance clinical outcomes in patients with altered skin barrier function.